ScinoPharm Taiwan, Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 05, 2022 at 06:15 pm EDT
Share
ScinoPharm Taiwan, Ltd. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was TWD 805.54 million compared to TWD 747.64 million a year ago. Net income was TWD 113.84 million compared to TWD 90.7 million a year ago. Basic earnings per share from continuing operations was TWD 0.14 compared to TWD 0.11 a year ago. Diluted earnings per share from continuing operations was TWD 0.14 compared to TWD 0.11 a year ago.
For the six months, sales was TWD 1,543.48 million compared to TWD 1,388.77 million a year ago. Net income was TWD 191.08 million compared to TWD 180.94 million a year ago. Basic earnings per share from continuing operations was TWD 0.24 compared to TWD 0.23 a year ago. Diluted earnings per share from continuing operations was TWD 0.24 compared to TWD 0.23 a year ago.
ScinoPharm Taiwan Ltd is a Taiwan-based company mainly engaged in the research, development, manufacture and sale of active pharmaceutical ingredients. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The Company is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The Company operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
SCINOPHARM TAIWAN, LTD. 
